Advancing longevity research is about honoring the value of life—and translating that respect into evidence-based prevention. If healthcare is judged by life expectancy + quality of life, longevity medicine may be one of the most meaningful metrics we can pursue: extending health span through early detection, validated biomarkers, and interventions that scale. This unforgettable Expert Panel from the 4th annual Medical Innovation Olympics (#MIO2025) convened all-star global leaders in Longevity and Preventive Medicine who separated hype from reality and outlined what it will take to bring longevity into mainstream care - rigorously, ethically, and accessibly. Topics include: breakthroughs (including epigenetic approaches pointing toward functional restoration of eyesight), biomarkers/endpoints as the “keystone” for faster trials, the TAME (Targeting Aging with Metformin) concept, and the role of standards, education, trust, and shared responsibility—keeping dignity central. Panelists: Dr. David Barzilai (Harvard Medical School; Geneva College of Longevity Science, GCLS) • Dr. Dominik Thor (President, GCLS) • Dr. Mishkat Shehata (Emirates Lifestyle & Longevity Medicine Society) • Keith Comito (Lifespan Research Institute) • Dr. Uma Senthilkumar (Three Five Revive) 🔗 Amedea Pharma: www.amedeapharma.com 🏅 Medical Innovation Olympics: #MIO2025 🎧 Subscribe for more episodes on longevity, innovation, and performance in healthcare. #MIO2025 #LongevityMedicine #Healthspan #AgingResearch #PreventiveMedicine #AmedeaPharma #Alloutcoach 00:00:00 Highlight 1: Four takeaways: fund research, education, transparency and 00:01:16 Highlight 2: TAME trial explained: endpoints beyond one disease 00:02:05 Highlight 3: “Do something now”: Alzheimer’s screening + vocal diagnostics 00:02:43 Highlight 4: Multi-omics: organ ages, pace of aging, microbiome, proteomics 00:03:54 Highlight 5: Meaning of longevity: purpose, shared responsibility, dignity 00:04:41 Highlight 6: Present Longevity Medicine as an Economic Benefit 00:05:58 Host Welcome: Longevity as duty, continuity, 00:09:54 Which breakthroughs in longevity show biggest promise 00:11:15 Pharma signal: GLP-1s + industry entering “by proxy” to aging biology 00:12:44 Precision era: epigenetics + multi-omics become clinic-standard 00:14:19 Case study: epigenetic reprogramming restores vision in models 00:16:42 Breakthroughs needed in next 1–2 yrs for longevity to go mainstream 00:17:30 Composite biomarkers regulators & public can trust 00:19:14 Biomarkers → shorter trials + precision feedback loops 00:23:10 Regulatory fragmentation across countries 00:26:21 How do we fit longevity into health systems? 00:27:30 TAME trial: “aging as target” + diagnostics role in preventive care 00:30:36 Call to action: fund TAME + UAE leadership recognition 00:31:05 Steps you can take now: Alzheimer's vocal screening 00:36:05 Where can stakeholders intersect - take action anywhere they live? 00:37:00 How patients, biopharma, regulators, payers align on health span 00:39:12 Is the goal to live forever? Health span vs lifespan 00:39:49 Tithonus myth: why “health span” changes public acceptance 00:41:34 Lifespan vs health span—and “how about both?” 00:42:15 Q&A: How do we attract top talent into longevity research? 00:42:15 Economic + ethical case for talent/policymakers 00:44:37 Q&A: Categorizing aging as disease—impact on regulation/cost/access? 00:44:39 Most effective way to reduce suffering + economic burden; society-wide case 00:46:08 Longevity reflects dignity, vitality and purpose: “health span is a shared responsibility” 00:47:18 Mindset shift: passive consumers → active participants 00:47:46 Get involved: Lifespan + public engagement campaign 00:48:32 Education + trusted sources vs “abbreviated” biohacking info 00:49:30 Four calls to action: increase funding, training, evidence, & access 00:52:25 Closing
